Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts

Clinical Infectious Diseases

Volumn 44, Issue 3, 2007, Pages 402-409

  Segal, Brahm H ^a   Almyroudis, Nikolaos G ^a   Battiwalla, Minoo ^a   Herbrecht, Raoul ^e   Perfect, John R ^b   Walsh, Thomas J ^c   Wingard, John R ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOPHOSPHAMIDE; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANCER; CANDIDIASIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; EARLY DIAGNOSIS; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; INFECTION COMPLICATION; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL TRANSPLANTATION;

ANTIFUNGAL AGENTS; BETA-GLUCANS; BIOLOGICAL MARKERS; EVALUATION STUDIES; FEVER; FUNGI; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MANNANS; MYCOSES; NEOPLASMS; NEUTROPENIA; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TOMOGRAPHY, X-RAY COMPUTED; YEASTS;

EID: 33846434112     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510677     Document Type: Short Survey

References (74)

1. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine (Baltimore) 1998; 77:246-54.
2. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.
3. Marr KA, Carter RA, Grippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
4. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 986-9.
5. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38:1237-42.
6. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999-1008.
7. Kontoyiannis DP, Bodey GP, Hanna H, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma 2004; 45:139-41.
8. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl 1):48-66.
9. Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002; 17:113-20.
10. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743-6.
11. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-2.
12. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: a case control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-60.
13. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
14. Freifeld AG, Baden LR, Brown AE, et al. Fever and neutropenia. In: National Comprehensive Cancer Network Practice Guidelines in Oncology. Vol 1. 2005. Available at: http://www .nccn.org. Accessed 10 September 2006.
15. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061-5.
16. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101-11.
17. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine (Baltimore) 1976; 55:259-68.
18. Aisner J, Schimpff SC, Wiernik PH. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977; 86:539-43.
19. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86:668-72.
20. Bennett JE, Powers J, Walsh T, et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36(Suppl 3): S117-22.
21. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994; 73:2099-106.
22. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28:331-40.
23. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
24. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation [see comments]. N Engl J Med 1992; 326:845-51.
25. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-16.
26. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94:3230-46.
27. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: a meta-analysis of 16 randomized, controlled trials. Cancer 2000;89:1611-25.
28. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-71.
29. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
30. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391-402.
31. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001; 135:412-22.
32. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108:282-9.
33. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996; 32A:814-20.
34. Marr KA. Antifungal therapy for febrile neutropenia: issues in clinical trial design. Curr Opin Investig Drugs 2004; 5:202-7.
35. Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004; 100:581-9.
36. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-16.
37. de Pauw BE, Sable CA, Walsh TJ, et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl Infect Dis 2006; 8:31-7.
38. Pfaller MA, Messer SA, Mollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45:2862-4.
39. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857-69.
40. Pfeiler MA, Messer SA, Boyken L, Hollis RJ, Diekema DJ. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis 2003; 45:241-4.
41. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5:775-85.
42. Gonzalez GM, Tijerina R, Najvar LK, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002; 46:1352-6.
43. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.
44. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system infections. J Antimicrob Chemother 2005; 56:745-55.
45. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease with invasive filamentous fungal infection. Clin Infect Dis 2005; 40:1684-8.
46. Kontoyiannis DP, Hare R, Solomon H, Corrado M, van Burik JA. Posaconazole is highly effective as a second-line agent in zygomycosis: summary of 91 cases [abstract M-974]. In: Program and abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: 2005.
47. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50:126-33.
48. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42:1179-86.
49. Cornely O, Maertens J, Winston D, et al. Posaconazole vs. standard azole (FLU/ITRA) therapy for prophylaxis of invasive fungal infections (IFIs) among high-risk neutropenic patients: results of a randomized, multicenter trial [abstract 1844]. Blood. 2005; 106.
50. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-24.
51. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29:15-9.
52. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19:801-8.
53. McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993; 17:397-404.
54. Yuen KY, Woo PC, Ip MS, et al. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997; 25:37-42.
55. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-66.
56. Shaukat A, Bakri F, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 2005; 159:181-8.
57. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 2003; 2:2.
58. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138:705-13.
59. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is impacted by azole antifungals. Blood 2003; 22:22.
60. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole (POS) vs. Fluconazole (FLU) for prophylaxis for invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-ver-sus-host disease (GVHD): results of a multicenter trial [abstract M-716]. In: Program and abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: 2005.
61. Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 2003; 5:158-66.
62. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4:349-57.
63. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641-9.
64. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762-9.
65. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20:1898-906.
66. Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42:4744-8.
67. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349:2366-7.
68. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-27.
69. Odabasi Z, Mattiuzzi G, Estey E, et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199-205.
70. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-9.
71. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
72. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus gancidovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99:1159-64.
73. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50.
74. Wingard JR. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 2004; 39(Suppl 4): S176-80.